Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
The new owner of hospitals embroiled in a for-profit company's bankruptcy vows to revamp patient safety measures.
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE and next-generation, highly selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback